163 results on '"Cybulska, Barbara"'
Search Results
2. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
3. Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum
4. Stanowisko dotyczące postępowania w rodzinnej hipercholesterolemii u dzieci i młodzieży. Stanowisko Forum Ekspertów Lipidowych
5. Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum
6. Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data
7. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
8. 2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland
9. The Mechanism of Overcoming Multidrug Resistance (MDR) of Fungi by Amphotericin B and Its Derivatives
10. Chapter 9 Interaction of Polyene Macrolide Antibiotics with Lipid Model Membranes
11. Current state-of-the-art knowledge on the role of omega-3 fatty acids in the prevention of cardiovascular disease
12. Hypolipaemic nutraceutics: red yeast rice and Armolipid, berberine and bergamot
13. Lipemia poposiłkowa — problem kliniczny i potencjalne miejsce w algorytmach diagnostycznych Stanowisko polskich ekspertów
14. Interaction of amphotericin B and its low toxic derivative, N-methyl- N-D-fructosyl amphotericin B methyl ester, with fungal, mammalian and bacterial cells measured by the energy transfer method
15. Wytyczne Polskiego Towarzystwa Diagnostyki Laboratoryjnej i Polskiego Towarzystwa Lipidologicznego dotyczące diagnostyki laboratoryjnej zaburzeń gospodarki lipidowej
16. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders
17. MFAME, N-methyl- N- d-fructosyl amphotericin B methyl ester, a new amphotericin B derivative of low toxicity: relationship between self-association and effects on red blood cells
18. Hypolipaemic nutraceutics: red yeast rice and Armolipid, berberine and bergamot.
19. Landmark studies in coronary heart disease epidemiology. The Framingham Heart Study after 70 years and the Seven Countries Study after 60 years
20. Recommendation for the management of dyslipidemia in Poland — Third Declaration of Sopot. Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy
21. How do we know that statins are diabetogenic, and why? Is it an important issue in the clinical practice?
22. Prevalence, diagnosis, and treatment of familial hypercholesterolaemia in outpatient practices in Poland
23. Kieszonkowe wytyczne PTL/KLRwP/PTK postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016
24. PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016
25. Functional Magnetic Resonance Imaging for breast cancer
26. Clinical management of heterozygous familial hypercholesterolemia in a Polish outpatient metabolic clinic: a retrospective observational study
27. Polish Forum for Prevention Guidelines on Dyslipidaemia: update 2016
28. Wytyczne PTL/KLRwP/PTK dotyczące postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016
29. PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016
30. Farmakoterapia skojarzona w heterozygotycznej rodzinnej hipercholesterolemii
31. Poprawa skuteczności osiągania celu terapeutycznego w zakresie docelowego stężenia cholesterolu frakcji LDL u pacjentów po ostrym zespole wieńcowym. Stanowisko grupy ekspertów
32. Czy trzeba zmniejszać stężenie cholesterolu u osób starszych?
33. Severe hypercholesterolaemia — when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts’ group statement
34. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey
35. Current issues in management of dyslipidemia : Declaration of Sopot Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy
36. Homocysteine — is it still an important risk factor for cardiovascular disease?
37. What do we know about lipoprotein(a)?
38. Why fast food should be forbidden in Polish schools?
39. Polish Forum for Prevention Guidelines on dyslipidaemia
40. Actual problems of dyslipidaemia treatment in Poland — 2nd Declaration of Sopot. Experts’ Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy
41. The HDL paradox: what does it mean and how to manage low serum HDL cholesterol level?
42. Management of severe hypertriglyceridaemia
43. Management in familial hypercholesterolaemia in children and adolescents. Position of the Lipid Expert Forum
44. What does obesity paradox mean in coronary heart disease?
45. Primary prevention of cardiovascular disease and other chronic noncommunicable diseases in the centre of attention of the United Nations: special importance of a prudent diet
46. Ciężka hipercholesterolemia -- kiedy stosować inhibitory proproteinowej konwertazy subtilizyny/kexiny 9 (inhibitory PCSK9)? Stanowisko grupy ekspertów Polskiego Towarzystwa Kardiologicznego.
47. Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum
48. Achieving target low‑density lipoprotein cholesterol levels in the Polish population
49. Studies of the Effects of Antifungal Cationic Derivatives of Amphotericin B on Human Erythrocytes
50. Facilitated diffusion of glucosamine-6-phosphate synthase inhibitors enhances their antifungal activity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.